世界の抗ウイルス治療薬市場：薬剤タイプ別、流通チャネル別 - 成長、動向、予測
Anti-Viral Therapeutics Market - Growth, Trends, and Forecast (2020 - 2025)
|世界の抗ウイルス治療薬市場：薬剤タイプ別、流通チャネル別 - 成長、動向、予測|
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 114 Pages
The anti-viral therapeutics market is expected to register a CAGR of 6.0%, over the forecast period. North America dominates the market, owing to the growing prevalence of hepatitis C and human immunodeficiency viruses (HIV) infections, coupled with the presence of a huge patient pool suffering from virally infectious diseases.
By Drug Type, HIV Anti-viral Drugs Mainly Boost the Global Market
HIV is a major global public health issue. According to the 2019 UNAIDS data, 24.5 million people were accessing antiretroviral therapy by the end of 2019. About 1.7 million people became newly infected with the virus in 2018. The vast majority of people living with HIV are located in low- and middle-income countries, with an estimated 66% living in Sub-Saharan Africa. However, the majority of HIV anti-viral consumption was exhibited in the North American region. Over the forecast period, the use of anti-virals in African countries is expected to increase multifold, as the majority of global companies are strategizing their HIV-based products in the emerging market.
North America is Expected to Dominate the Market over the Forecast Period
North America dominated the anti-viral therapeutics market, owing to the presence of well-established market players, as well as due to the growing prevalence of HIV and hepatitis C infections. The North American market is primarily driven by factors, such as the increasing occurrence of infectious diseases, increasing geriatric population base, and growing healthcare awareness, coupled with increasing healthcare expenditure in the region. However, there are limitations to market growth in the region, which include generic erosion and patent expiration of anti-viral drugs.
The anti-viral therapeutics market is a fast-growing market. The current market share is majorly controlled by a few major pharmaceutical and biotechnology companies. There is a limited number of antiviral products in the market, and a large percentage of these drugs is expected to lose exclusivity in the coming future. This may be marked by the entry of generic manufacturers, expansion of market size, and lowering of market concentration.